AstraZeneca and MRC Technology are launching an initiative to find new epigenetic targets in respiratory disease. By picking promising academic research, the two parties expect to lock in new drugs for diseases like asthma.
After partnering up with genomics elite for a new biobank, AstraZeneca is again preparing to tap into collaborations with academia. This time, the objective is to leverage new research in the field of epigenetics – the ‘next frontier‘ (after genomics) that even has its own ‘Illumina’ lined up.
One institute that is already on board is MRC Technology (MRCT). This medical research charity started out in 2000 to aid technology transfer at the Medical Research Council (which famously pioneered monoclonal antibodies).
Together, the two are opening a call for researchers working in epigenetic mechanisms involved in respiratory diseases – such as chronic obstructive pulmonary disease (COPD) and asthma.
In addition, they are also interested in epigenetic modulators acting in biological pathways relevant to respiratory,